Joint ARIO and COGR working groups have developed several tools to assist institutions in revising their research misconduct policies t
Research Integrity & Misconduct
Ensuring that research is conducted in a transparent, objective and verifiable manner, along with regulatory requirements governing the reporting and review of allegations of fabrication, falsification and plagiarism in scientific research.
Featured
Who's Got Guidance: Results from the ARIO/COGR Survey of Research Integrity Officials on the Final ORI Research Misconduct Rule
The survey conducted by the Association of Research Integrity Officers (ARIO) and COGR assessed how research integrity officials view the implementation of the...
Resources
Point of Contact
Kristin West
Director, Research Ethics & Compliance
All Research Integrity & Misconduct Articles
ARIO and COGR Post Tools for Finalizing Institutional Research Misconduct Policies to Comply with Updated PHS Regulations at 42 CFR Part 93
Joint ARIO and COGR working groups have developed several tools to assist institutions in revising their research misconduct policies to comply with the updated PHS Research Misconduct Regulations at 42 CFR Part 93. Institutions are expected to have revised policies in place by January 1, 2026, when updates to the regulations will all be fully applicable.
Decision Point Slide Presentation ARIO COGR September 2025 V.1
The document provides an in-depth guide for institutions on incorporating the 2024 Public Health Service (PHS) Research Misconduct Rule (42 CFR Part 93) into their research misconduct policies and procedures. It emphasizes the new flexibilities introduced in the 2024 Rule and outlines key decision points institutions must consider, such as the distinction between what is established in policy vers
July 2025 Update
The July 2025 COGR Update offers a comprehensive review of recent policy, legal, and regulatory developments affecting research institutions, with primary focus on federal funding, research security, administrative burden, and the controversial 15% cap on indirect cost reimbursement. It details COGR’s advocacy—including legal actions and promotion of the FAIR Model—as well as significant federal a
